Press Release

« Back
Protagonist Therapeutics Announces PTG-200 Data Accepted for Oral Presentation at Digestive Diseases Week

MILPITAS, Calif., April 20, 2017 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today announced that preclinical research findings on PTG-200, the company's oral peptide IL-23 receptor antagonist, has been accepted for oral presentation on Saturday, May 6, 2017 at the Digestive Diseases Week® (DDW) conference. DDW, the world's largest gathering of physicians, researchers and industry in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery, is being held in Chicago, Illinois from May 6-9, 2017. Below are the details for the oral presentation.

Presentation Title: The Biomarker Profile of PTG-200, an Oral Peptide Antagonist of IL-23 Receptor, Tracks with Efficacy in a Preclinical Model of IBD
Date and Time: Saturday, May 6 from 11:15 AM to 11:30 AM CT
Location: McCormick Place, Room S102d

About Protagonist Therapeutics, Inc.

Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform which it uses to develop novel peptide drugs that address biological targets that have typically been approached by injectable antibody drugs. Protagonist's oral peptide product candidates, PTG-100 and PTG-200, have the potential for improved safety and compliance when compared to their approved antibody counterparts, given they have minimal exposure in the blood and improved convenience, thereby presenting an opportunity for earlier introduction of targeted therapy for inflammatory bowel disease (IBD). PTG-100 is currently in Phase 2b clinical trials for moderate-to-severe ulcerative colitis, and the company plans to initiate clinical trials of PTG-200 during 2017 as a potential treatment for Crohn's disease. Protagonist also plans to initiate clinical trials during 2017 of an injectable hepcidin mimetic, PTG-300, for the treatment of iron overload disorders such as beta-thalassemia, an indication which may qualify it for orphan drug designation.

Protagonist is headquartered in Milpitas, California with its pre-clinical and clinical development staff in California, and discovery operations both in California and in Brisbane, Queensland, Australia. For further information, please visit http://www.protagonist-inc.com.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our intentions or current expectations concerning, among other things, the potential for our programs, plans, timing and the availability of results of our clinical trials, enrollment in our clinical trials, capital resources, the possibility of obtaining orphan drug designation, and the potential for eventual regulatory approval of our product candidates. In some cases you can identify these statements by forward-looking words such as "may," "will," "continue," "expects," or the negative or plural of these words or similar expressions.  Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our history of net operating losses, our reliance on third parties and uncertainty regarding our ability to achieve profitability, our ability to develop and commercialize our product candidates, our ability to use and expand our programs to build a pipeline of product candidates, our ability to obtain and maintain regulatory approval of our product candidates, our ability to operate in a competitive industry and compete successfully against competitors that have greater resources than we do,  and our ability to obtain and adequately protect intellectual property rights for our product candidates.  We discuss many of these risks in greater detail under the heading "Risk Factors" contained in our Annual Report on Form 10-K for the year ended December 31, 2016, to be filed with the Securities and Exchange Commission concurrently herewith. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/protagonist-therapeutics-announces-ptg-200-data-accepted-for-oral-presentation-at-digestive-diseases-week-300443110.html

SOURCE Protagonist Therapeutics, Inc.

Joan Kureczka, Kureczka/Martin Associates, Tel: +1 415-821-2413, Mobile: +1 415-690-0210, Email: Joan@Kureczka-martin.com; For Investors: The Trout Group, Marcy Nanus, Tel: +1 646-378-2927, Email: mnanus@troutgroup.com